Log In
Print this Print this

guselkumab (CNTO 1959)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionHuman HuCAL mAb targeting the p19 subunit of Interleukin-23 (IL-23)
Molecular Target Interleukin-23 (IL-23)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today